Cat. No.: HY-19952

Pleconaril

(Synonyms: VP 63843; Win 63843)

1 Cited Publications

Avis client

Based on 1 publication(s) in Google Scholar

Pleconaril is a picornavirus capsid binding inhibitor that prevents attachment and/or virus uncoating. Pleconaril has potential for use in rhinoviruses and enteroviruses research.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.71%
CAS No.: 153168-05-9
Formule: C₁₈H₁₈F₃N₃O₃
Masse moléculaire:381.35

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Pleconaril Chemical Structure

CAS No.: 153168-05-9

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (1)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Pleconaril is a picornavirus capsid binding inhibitor that prevents attachment and/or virus uncoating. Pleconaril has potential for use in rhinoviruses and enteroviruses research^[1]^[2].

Cellular Effect

Cell Line	Type	Value	Description	References
H1-HeLa	CC₅₀	19.7 μM Compound: 1	Cytotoxicity against human H1HeLa cells assessed as decrease in cell viability after 3 days by MTT assay Cytotoxicity against human H1HeLa cells assessed as decrease in cell viability after 3 days by MTT assay	[PMID: 28581749]
H1-HeLa	CC₅₀	53.5 μM Compound: Pleconaril	Cytotoxicity in human H1HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxicity in human H1HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 28587824]
H1-HeLa	CC₅₀	19.7 μM Compound: Pleconaril	Cytotoxicity against human H1HeLa cells assessed as reduction in cell viability after 3 days by MTT assay Cytotoxicity against human H1HeLa cells assessed as reduction in cell viability after 3 days by MTT assay	[PMID: 30034598]
H1-HeLa	CC₅₀	20.8 μM Compound: Pleconaril	Cytotoxicity against human H1-HeLa cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human H1-HeLa cells assessed as reduction in cell viability by MTT assay	[PMID: 35292344]
H1-HeLa	CC₅₀	20.3 μM Compound: Pleconaril	Cytotoxicity against human H1-HeLa cells infected with 1 MOI human rhinovirus 14 pretreated with compound for 1 hr followed by viral infection measured by MTT assay Cytotoxicity against human H1-HeLa cells infected with 1 MOI human rhinovirus 14 pretreated with compound for 1 hr followed by viral infection measured by MTT assay	[PMID: 38389877]
HeLa	CC₅₀	12.6 μg/mL Compound: pleconaril	Cytotoxicity against human HeLa cells after 72 hrs Cytotoxicity against human HeLa cells after 72 hrs	[PMID: 18247552]
HeLa	IC₅₀	0.01 μg/mL Compound: pleconaril	Antiviral activity against HRV2 in HeLa cells Antiviral activity against HRV2 in HeLa cells	[PMID: 18247552]
HeLa	IC₅₀	0.02 μg/mL Compound: pleconaril	Antiviral activity against HRV14 in HeLa cells Antiviral activity against HRV14 in HeLa cells	[PMID: 18247552]
HeLa	IC₅₀	0.02 μg/mL Compound: pleconaril	Antiviral activity against HRV16 in HeLa cells Antiviral activity against HRV16 in HeLa cells	[PMID: 18247552]
HeLa	IC₅₀	0.02 μg/mL Compound: pleconaril	Antiviral activity against HRV1A in HeLa cells Antiviral activity against HRV1A in HeLa cells	[PMID: 18247552]
HeLa	EC₅₀	224.1 ng/mL Compound: 1	Antirhinoviral activity against Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	23.2 ng/mL Compound: 1	Antirhinoviral activity against minor receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against minor receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	33.8 ng/mL Compound: 1	Antirhinoviral activity against antiviral-resistant Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against antiviral-resistant Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	37.4 ng/mL Compound: 1	Antirhinoviral activity against Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	387.6 ng/mL Compound: 1	Antirhinoviral activity against antiviral-resistant Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against antiviral-resistant Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	49.2 ng/mL Compound: 1	Antirhinoviral activity against major receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antirhinoviral activity against major receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24900468]
HeLa	EC₅₀	177 nM Compound: Pleconaril	Antienteroviral activity against Human rhinovirus 14 infected in human HeLa cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against Human rhinovirus 14 infected in human HeLa cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
HeLa	CC₅₀	25.9 μM Compound: 1	Cytotoxicity aganist human HeLa cells assessed as decrease in cell viability after 2 days by MTT assay Cytotoxicity aganist human HeLa cells assessed as decrease in cell viability after 2 days by MTT assay	[PMID: 28581749]
HeLa	EC₅₀	1.4 μM Compound: 1	Antiviral activity against Human poliovirus 3 infected in human HeLa cells assessed as protection against virus induced cytopathic effect after 2 days by MTT assay Antiviral activity against Human poliovirus 3 infected in human HeLa cells assessed as protection against virus induced cytopathic effect after 2 days by MTT assay	[PMID: 28581749]
HeLa	CC₅₀	42.8 μM Compound: Pleconaril	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 28587824]
HeLa	EC₅₀	>42.8 μM Compound: Pleconaril	Antiviral activity against human coxsackievirus B3 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay Antiviral activity against human coxsackievirus B3 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay	[PMID: 28587824]
HeLa	EC₅₀	0.13 μM Compound: Pleconaril	Antiviral activity against human coxsackievirus B1 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay Antiviral activity against human coxsackievirus B1 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay	[PMID: 28587824]
HeLa	EC₅₀	0.51 μM Compound: Pleconaril	Antiviral activity against human poliovirus 3 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay Antiviral activity against human poliovirus 3 infected in human HeLa cells assessed as reduction in virus-induced cytopathicity incubated for 3 days by MTT assay	[PMID: 28587824]
HeLa	CC₅₀	131 μM Compound: Pleconaril	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 29039946]
HeLa	IC₅₀	≤0.18 μM Compound: 55; WIN63843	Cytotoxicity against human HeLa cells after 3 days by MTT assay Cytotoxicity against human HeLa cells after 3 days by MTT assay	[PMID: 31226653]
HeLa	CC₅₀	26.25 μM Compound: Pleconaril	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs measured by crystal violet based micro plate reader method Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs measured by crystal violet based micro plate reader method	[PMID: 31881489]
RD	EC₅₀	13400 nM Compound: Pleconaril	Antienteroviral activity against Enterovirus 71 infected in human RD cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against Enterovirus 71 infected in human RD cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
RD	CC₅₀	>200 μM Compound: 1	Cytotoxicity against human RD cells assessed as inhibition of cell viability by measuring ATP level incubated for 72 hrs by cell titer-glo luminescent cell viability assay Cytotoxicity against human RD cells assessed as inhibition of cell viability by measuring ATP level incubated for 72 hrs by cell titer-glo luminescent cell viability assay	[PMID: 36254462]
Vero	EC₅₀	1084 nM Compound: Pleconaril	Antienteroviral activity against poliovirus 2 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against poliovirus 2 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
Vero	EC₅₀	24200 nM Compound: Pleconaril	Antienteroviral activity against poliovirus 1 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against poliovirus 1 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
Vero	EC₅₀	33 nM Compound: Pleconaril	Antienteroviral activity against Coxsackievirus A9 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against Coxsackievirus A9 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
Vero	EC₅₀	84 nM Compound: Pleconaril	Antienteroviral activity against poliovirus 3 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against poliovirus 3 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
Vero	EC₅₀	13 μM Compound: Pleconaril	Antienteroviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay Antienteroviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTS assay	[PMID: 24900715]
Vero	EC₅₀	0.005 μM Compound: Pleconaril	Antiviral activity against Coxsackievirus B5 infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay Antiviral activity against Coxsackievirus B5 infected in African green monkey Vero 76 cells after 3 days by plaque reduction assay	[PMID: 25913116]
Vero	EC₅₀	2.2 μM Compound: Pleconaril	Antiviral activity against Poliovirus Sb-1 infected in African green monkey Vero 76 cells after 2 days by plaque reduction assay Antiviral activity against Poliovirus Sb-1 infected in African green monkey Vero 76 cells after 2 days by plaque reduction assay	[PMID: 25913116]
Vero	IC₅₀	0.0025 μM Compound: pleconaril	Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 26110443]
Vero	IC₅₀	0.001 μM Compound: Pleconarild	Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 27792321]
Vero	CC₅₀	>1.05 μM Compound: Pleconaril	Cytotoxicity in African green monkey Vero cells assessed as reduction in cell viability Cytotoxicity in African green monkey Vero cells assessed as reduction in cell viability	[PMID: 32378892]
Vero	EC₅₀	0.002 μM Compound: Pleconaril	Antiviral activity against Coxsackievirus B3 infected in Vero cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by Reed-Muench method Antiviral activity against Coxsackievirus B3 infected in Vero cells assessed as reduction in virus-induced cytopathic effect incubated for 48 hrs by Reed-Muench method	[PMID: 32378892]
Vero 76	CC₅₀	80 μM Compound: Pleconaril	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method	[PMID: 25913116]
Vero 76	CC₅₀	70 μM Compound: Pleconaril	Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method	[PMID: 26443549]
Vero 76	EC₅₀	0.008 μM Compound: Pleconaril	Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay	[PMID: 26443549]
Vero 76	EC₅₀	2 μM Compound: Pleconaril	Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay	[PMID: 26443549]
Vero 76	CC₅₀	83 μM Compound: Pleconaril	Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay	[PMID: 29028528]
Vero 76	CC₅₀	>100 μM Compound: Pleconaril	Cytotoxicity against African green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay Cytotoxicity against African green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	[PMID: 29339251]

In Vitro

Pleconaril (0.4-50 µM, 2 days) produces substantial cytotoxicity at 50 μM concentrations in RD cells^[2].
Pleconaril (0.001-4 µg/mL, 24 h) increases the cell viability of RD cells infected with EV71^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pleconaril (0.375-80 mg/kg, i.p., daily, 5 days) increases the number of viable mice infected with EV71^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 153168-05-9
Appearance Solid
Masse moléculaire 381.35
Formule C₁₈H₁₈F₃N₃O₃
Color White to off-white
SMILES

FC(C1=NC(C2=CC(C)=C(OCCCC3=CC(C)=NO3)C(C)=C2)=NO1)(F)F
Synonyms

VP 63843; Win 63843
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (1)

All

Sort by:

Journal Impact Factor

iScience

Quantitative virus infectivity titration and dose-response analyses using cell-culture based methods and python code-assisted data analysis. [Abstract]

2026 Feb 13;29(3):115018. PMID: 41809041

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (262.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6223 mL

13.1113 mL

26.2226 mL

5 mM

0.5245 mL

2.6223 mL

5.2445 mL

10 mM

0.2622 mL

1.3111 mL

2.6223 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.56 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.56 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (271 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Benschop KS, et al. Genetic and antigenic structural characterization for resistance of echovirus 11 to pleconaril in an immunocompromised patient. J Gen Virol. 2015 Mar;96(Pt 3):571-9. [Content Brief]

[2]. Lee JS, et al. Antiviral Activity of Itraconazole against Echovirus 30 Infection In Vitro. Osong Public Health Res Perspect. 2017 Oct;8(5):318-324. [Content Brief]

[3]. Zhang G, et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol. 2012 Apr;157(4):669-79. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6223 mL	13.1113 mL	26.2226 mL	65.5566 mL
	5 mM	0.5245 mL	2.6223 mL	5.2445 mL	13.1113 mL
	10 mM	0.2622 mL	1.3111 mL	2.6223 mL	6.5557 mL
	15 mM	0.1748 mL	0.8741 mL	1.7482 mL	4.3704 mL
	20 mM	0.1311 mL	0.6556 mL	1.3111 mL	3.2778 mL
	25 mM	0.1049 mL	0.5245 mL	1.0489 mL	2.6223 mL
	30 mM	0.0874 mL	0.4370 mL	0.8741 mL	2.1852 mL
	40 mM	0.0656 mL	0.3278 mL	0.6556 mL	1.6389 mL
	50 mM	0.0524 mL	0.2622 mL	0.5245 mL	1.3111 mL
	60 mM	0.0437 mL	0.2185 mL	0.4370 mL	1.0926 mL
	80 mM	0.0328 mL	0.1639 mL	0.3278 mL	0.8195 mL
	100 mM	0.0262 mL	0.1311 mL	0.2622 mL	0.6556 mL

Keywords

Pleconaril

1 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Pleconaril

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

Pediatric Drug Library

Protein-protein Interaction Inhibitor Library

Human Metabolite Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Anti-Infection Compound Library

Clinical Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Pleconaril

Activité biologique

Chemical Information

Publications (1)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Pleconaril

FDA Approved & Pharmacopeial Drug Library

Rare Diseases Drug Library

Pediatric Drug Library

Protein-protein Interaction Inhibitor Library

Human Metabolite Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Anti-Infection Compound Library

Clinical Compound Library

Antiviral Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Pleconaril

Activité biologique

Chemical Information

Publications (1)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Pleconaril Related Classifications

HY-19952 Related Classifications